Seeking Alpha

The FDA says it can't conclude that Novartis' (NVS) multiple sclerosis drug Gilenya was...

The FDA says it can't conclude that Novartis' (NVS) multiple sclerosis drug Gilenya was connected to the unexplained deaths of patients, although the agency is still worried about the cardiovascular effects of the treatment following the first dose.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs